Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1820)	3/13/2003 2:33:49 AM
From: tuck	Read Replies (1) \| Respond to of 2243

I may get hissed at, but perhaps RIGL could make it as 50 bagger. It would only have to get to about $30 to do it now. They'll have to finance this year. Their strategy is to partner after PII. Their lead compound for allergic rhinitis is in PII, and I would expect that trial to wrap up pretty quickly. They said efficacy data would be out mid year. Should they get a partner and cash infusion to keep all the other programs running before they run out, then fine, they could be on their way. If not, dilution hell, and a few bags at best. R803 for Hep C goes into the clinic in the second half. High risk, but so are all 50 baggers. Perhaps a few milestones will come in from Pfizer, J&J, and Daichi. Wilder may know more of the possible timing of those; failing that, a call to IR. Cheers, Tuck